Original article

Evaluation of the antioxidative and genotoxic effects of sodium butyrate on breast cancer cells

Burcu Yuksel a,⇑, Asuman Deveci Ozkan b, Duygu Aydin c, Zeynep Betts c

aDepartment of Medical Services and Techniques, Kocaeli Vocational School of Health Services, Kocaeli University, Kocaeli, Turkey
bDepartment of Medical Biology, Faculty of Medicine, Sakarya University, Sakarya, Turkey
cDepartment of Biology, Faculty of Science and Literature, Kocaeli University, Kocaeli, Turkey

A R T I C L E  I N F O

Article history:
Received 3 October 2021
Revised 23 December 2021
Accepted 28 December 2021
Available online 3 January 2022

Keywords:
Breast cancer
Comet assay
Sodium butyrate
Nitric oxide

A B S T R A C T

Oncogenic stimulation shows a rise in reactive oxygen species (ROS), and ROS can eventually induce carcinogenesis by causing DNA damage. In this context, this study aims to evaluate some biochemical and genotoxic changes in the control of cell death caused by NaBu (Sodium butyrate) treatment in breast cancer cells. NaBu's impact on cell proliferation was determined via WST-1 assay. The lipid peroxidation (MDA), reduced glutathione (GSH), Nitric Oxide (NO), hydrogen peroxide (H2O2), and superoxide dismutase (SOD) enzyme levels were determined biochemically. NaBu-induced genotoxic damage was estimated via single-cell gel electrophoresis (SCGE). NaBu reduced cell viability and potentially induced GSH, but decreased SOD enzyme activity and the level of MDA and NO decreased also H2O2 decreased at different times and NaBu concentrations. Higher NaBu concentrations amplified DNA damage in MCF-7 cells compared to the control group. NaBu shows anticancer and genotoxic effects, especially through antioxidant enzymes, one of the oxidative stress parameters in breast cancer. However, the anticancer and genotoxic effects of NaBu is changed in the oxidative stress parameters with time and treatment concentration of NaBu in MCF-7 cells. Furthermore, his oxidative stress-dependent effect changes need to be clarified by further evaluation with molecular and more biochemical parameters.

© 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Oncogenic stimulation increases reactive oxygen species (ROS) in cancer cells due to amplified metabolic activity and mitochondrial damage (Khan et al., 2012). The mitochondrial respiratory chain is the primary basis of ROS production in cells, and ROS caused by cancer cells causes bigger stress (Mansoor et al., 2016; Moloney and Cotter, 2018). ROS causes cytotoxicity at high oxidative stress and can induce apoptosis by inhibiting cell proliferation. In addition, when in a low or moderate oxidative stress state, ROS can eventually induce carcinogenesis by causing DNA damage, cell mutation, inflammation, and cell proliferation (Fang et al., 2009). On the other hand, antioxidants including superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase are among compounds that can reduce ROS (Atala et al., 2017; Chio and Tuveson, 2017; Yuksel and Deveci Ozkan, 2021). Malondialdehyde (MDA), the major polyunsaturated fatty acid peroxidation, is toxic. Its interaction with DNA and proteins is usually regarded as hypothetically mutagenic atherogenic and is a major contributor to DNA damage and mutation (Del Rio et al., 2005; Ayala et al., 2014). H2O2 is long-lived in plasma and has important effects for selective induction of apoptosis in tumour cells and that cancer cells produce high amounts of H2O2 (López-Lázaro, 2007; Bauer, 2019). Superoxide dismutases (SOD) are essential enzymes that protect cells from damage against free radicals by eliminating superoxide radicals (O-2) (Huang et al., 2000). Studies show that SOD activity and expression are significantly altered in gastric cancer patients (Yi et al., 2010). The key antioxidant enzyme that ruminates the superoxide anion radical in mitochondria is manganese superoxide dismutase (MnSOD). MnSOD has a critical function in the growth and progression of cancer (Dhar and Clair, 2012). Reduced glutathione (GSH) plays an essential function in cell biology. It has an important function in most human diseases, such as cancer and cardiovascular diseases, by acting in cellular protection against xenobiotics, free radicals and naturally harmful compounds.
including hydroperoxides (Locigno and Castronovo, 2001; Traverso et al., 2013). Since the balance between the number of oxidants and antioxidants affects cancer cell metabolism, it is important to determine these parameters in evaluating the effects of substances with anticancer potential (Isnaini et al., 2018).

The acetylation status of genes controlled via histone acetyltransferases (HAT) and Histone deacetylases (HDAC) acts like a vital regulatory mechanism to control gene expression and chromatin structure (Glozak et al., 2005; Bolden et al., 2006). Sodium butyrate (NaBu), a short-chain fatty acid serving as a histone deacetylase inhibitor (HDACi), is a byproduct of carbohydrate metabolism in the gut and has been reported acting as a possible regulator of cancer cell death (Li et al., 2015; Salimi et al., 2017). It also has important roles in various mechanisms and cellular processes, including cell proliferation, differentiation induced cancer cell growth, DNA double-strand break repair, oxidative stress inhibition and gene expression (Grabarska et al., 2013; Falkenberg and Johnstone, 2014; Eckschlager et al., 2017). It is also known that NaBu induces apoptosis in many cancers (Natoni et al., 2005; Li et al., 2014; Salimi et al., 2017). Moreover, NaBu exhibits good anti-cancer activity. It can cause relaxation of the chromatin structure and provide improved adhesion to transcription-related proteins and is therefore widely used in the clinical treatment of many tumours (Jazirehi, 2010).

Breast cancer is the top cancer type in women, other than non-melanoma skin cancer, and among the cases diagnosed in women, 1 in 4 cancers is breast cancer (Bray et al., 2018; Zendehdel et al., 2019). Since breast cancer treatment (Hosford and Miller, 2014).

2. Materials and methods

2.1. Cell culture

In this study, MCF-7 breast cancer cells were used. The cells were commercially acquired from the American Type Culture Collection (ATCC). MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco), including 10% heat-inactivated fetal bovine serum (FBS, Sigma Aldrich) and 0.1% penicillin/streptomycin in a humidified incubator at 37°C with 5% CO₂.

2.2. Cell viability assay

The cytotoxic impact of NaBu on MCF-7 cells was determined via WST-1 analysis. For this purpose, the cells were seeded in 96-well plates at 2 × 10⁴ cells/well and incubated for 24 and 48 h with different concentrations of NaBu (1, 2.5, 5 and 10 mM). After incubation, the cells were incubated with WST-1 solution for 45 min. Later, the cells were analyzed using the optical reader (BioTek Instrument ELISA reader) at 450 nm absorbance. MCF-7 cells were incubated in a growth medium without NaBu accepted as a negative control, and the viability of the negative control group was considered 100%. The most effective exposure concentrations and time were selected for further experiments. Each experiment was performed in triplicate.

2.3. Biochemical analyses

2.3.1. Preparation of the cell lysates

To find out the impact of NaBu on oxidative stress parameters in MCF-7 cells, cell lysates were isolated. To this end, the cells (5 × 10⁴) were seeded in 6-well plates and processed with NaBu (1 and 5 mM) for 24 and 48 h. After treatment, cells were treated with RIPA cell lysis buffer (Sigma Aldrich) and centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant obtained after centrifugation was utilized to analyze antioxidant enzyme activity and oxidative stress analysis.

2.3.2. Determination of malondialdehyde (MDA) level

Malondialdehyde detection was based on the method of Heath and Packer (Heath and Packer, 1968). TCA (Trichloroacetic acid) solution (20%) containing 100 μl cell lysate and 1400 μl of 0.5% TBA (Thiobarbutyrlic acid) was mixed. The mixture was incubated in an oven at 100°C for 60 min. Then, the samples were taken on ice, and when they reached room temperature, they were centrifuged at 1500g for 5 min. The supernatant was read at 532 nm and 600 nm in a spectrophotometer and calculated according to the formula of 155 cm⁻¹ M⁻¹ below.

\[
\text{Malondialdehyde Amount (\text{\mu M})} = \frac{A_{532} - A_{4600}}{155} \times 1000 \times \text{dilution factor}
\]

2.3.3. Determination of hydrogen peroxide (H₂O₂) and nitric oxide (NO) level

The quantity of hydrogen peroxide was calculated based on the study of Alexieva et al., (2001). A total of 1.5 ml of a solution containing 0.25 ml of cell lysate, 0.25 ml of 100 mM potassium phosphate buffer solution (pH 7) and 1 ml of 1 M potassium iodide (KI) (prepared with fresh bidistilled water) was prepared and mixed. The cell lysate was stored in the dark at +4°C for 1 h to react with KI. The samples were then measured at 390 nm in a spectrophotometer. Nitric oxide (NO) levels were determined with the Nitrite Oxide Colorimetric Assay kit (Elabscience).

2.3.4. Determination of the SOD enzyme activity

As substrate buffer for SOD enzyme determination, 50 mM potassium phosphate buffer (pH 7.8), 9.9 mM L-methionine, 57 mM NBT (Nitroblue tetrazolium chloride), 0.025% (w/v) Triton X-100, 0.0044% (w/v) riboflavin were prepared. The solution was dissolved by stirring in a mixer for 30 min and then incubated at +4°C (Dixit et al., 2001). The substrate buffer and 0.05 ml of cell lysate were mixed and incubated under a 21-Watt fluorescent lamp for 15 min. The enzyme-free substrate buffer was kept under light for 15 min and used blindly (Tripathi and Gaur, 2004; Mishra et al., 2009).
et al., 2006). Then, a sample was estimated at 560 nm in a spectrophotometer, and the amount of enzyme was taken as U mg⁻¹.

\[
\text{Unit} = \frac{\text{Amount of sample in cuvette}}{\text{Unit of sample}} = \frac{\text{Amount of sample in cuvette}}{50} \times \frac{\text{Dilution Factor}}{\text{Amount of enzyme}}
\]

2.3.5. Determination of the amount of reduced glutathione (GSH)

Determination of the amount of GSH was based on the study of Kumar et al., (2011). Cell lysate and sulfosalicylic acid (4%) were mixed and incubated at +4 °C for 1 h and centrifuged at 1200 g at +4 °C for 15 min. The supernatant was added to 2.7 ml of potassium phosphate buffer (0.1 M, pH 7.4) and 200 μl of 5.5 dithiobis-(2-nitro benzoic acid) (Ellman’s reagent, 0.1 mM, pH 8.0). The samples were measured at 412 nm in a spectrophotometer, and the buffer was used as a blank. GSH level was calculated according to the formula 1.36 × 10⁴ M⁻¹ cm⁻¹ and expressed as micromole per milligram protein.

2.4. Single-cell gel electrophoresis (SCGE) analysis

The cells were seeded in 6-well plates at 1 × 10⁵ cells/well and incubated with different concentrations of NaBu (1 and 5 mM) for 24 and 48 h. After incubation, cells were harvested by trypsinization resuspended in ice-cold PBS. After the slides were first covered with 1% NMP (Normal melting point agar), 75 μl of 1% LMP (Low melting point, prepared with 0.01 M PBS) agar and 50 μl of cell suspension were added and incubated on ice for 15 min. Slides were incubated in lysis solution (2.5 M NaCl, 100 mM Na₂EDTA, 10 mM Tris, 1% Triton X-100, and pH 10) for 1 h. Then, they were kept in electrophoresis buffer (300 mM NaOH, 1 mM Na₂EDTA, pH > 13) at +4 °C for 15 min. Then, electrophoresis was performed at 25 V, 300 mA for 15 min. After electrophoresis, the slides were kept in cold 0.4 M Tris buffer solution (pH 7.5), distilled water and finally 96% ethanol. The slides were stained with 60 μl (2 μg/ml) Ethidium Bromide, washed twice with distilled water, covered with a coverslip, and examined under a fluorescent microscope (DP71, Olympus) on a 515–560 nm filter. A total of 150 comets were counted, 50 from each slide and my camera was analyzed with CometScore Software.

2.5. Statistical analysis

During statistical analysis, one-way variance analysis (ANOVA) with Tukey’s post hoc and Mann-Whitney U tests were used. Obtained results were reported as a mean ± standard error of the mean (SD), and all experiments were conducted in triplicate. The p < .05 value was statistically significant, and GraphPad Prism 16 was employed while conducting statistical analysis.

3. Results

3.1. Evaluation of the cytotoxic effect of NaBu on MCF-7 cells

To estimate the most effective exposure concentrations and time of NaBu, WST-1 analysis was conducted. The results showed that NaBu exerted a cytotoxic effect on MCF-7 cells in a dose and time-dependent manner, as shown in Fig. 1. After 24 h of treatment with NaBu (1, 2.5, 5 and 10 mM), the growth rate of MCF-7 cells significantly reduced to 90.5%, 68.1%, 65.5% and 67.8%, respectively (p < .001; Fig. 1). Additionally, the viability of MCF-7 cells significantly reduced to 73.8%, 62.1%, 52.8%, and 33.4% at concentration of 1, 2.5, 5 and 10 mM NaBu, respectively for 48 h. As a result, our findings showed that the most effective exposure concentrations and time of NaBu were 1 mM and 5 mM and 24 h and 48 h, respectively. Therefore, 1 and 5 mM NaBu treatment were selected at 24 and 48 h time for further experiments.

3.2. The effects of NaBu on the MDA amounts

Our results determined that the amount of MDA (2.84 μM) of the cells incubated with 1 mM NaBu for 24 h decreased slightly compared to the control cells that were not treated with NaBu (3.07 μM). On the other hand, the data obtained with 5 mM NaBu showed an increase in the amount of MDA in MCF-7 cells compared to the control group (3.12 μM, 1.09-fold). At the end of the 48 h, the same results were obtained in cells treated with 1 mM NaBu (2.59 μM), compared to the control group, while an increase was observed in 5 mM NaBu treatments (3.085 mM, 1.18-fold) (Fig. 2). The mean values and statistical data of the changes in the amount of MDA in the control group, 1 mM NaBu and 5 mM NaBu treated MCF-7 cells, are given in Table 1.

3.3. The effects of NaBu on the H₂O₂ amounts

The H₂O₂ amounts of cells treated with 1 mM NaBu and 5 mM NaBu for 24 h increased compared to the control group (5.18 μM; 1.01 and 1.2-fold, respectively) (Fig. 1). In the data we received at the end of 48 h, a very serious decrease was observed in the amount of H₂O₂. As a result of 1 mM NaBu and 5 mM NaBu treatments compared to the control group (3.43 μM, 1.25-fold) (Fig. 2). In the data we received at the end of 48 h, a very serious decrease was observed in the amount of H₂O₂. As a result of 1 mM NaBu and 5 mM NaBu treatments compared to the control group (3.12 μM; 1.09-fold) (Fig. 2). In the data we received at the end of 48 h, a very serious decrease was observed in the amount of H₂O₂. As a result of 1 mM NaBu and 5 mM NaBu treatments compared to the control group (3.43 μM, 1.25-fold) (Fig. 2). In the data we received at the end of 48 h, a very serious decrease was observed in the amount of H₂O₂. As a result of 1 mM NaBu and 5 mM NaBu treatments compared to the control group (3.43 μM, 1.25-fold) (Fig. 2). In the data we received at the end of 48 h, a very serious decrease was observed in the amount of H₂O₂. As a result of 1 mM NaBu and 5 mM NaBu treatments compared to the control group (3.43 μM, 1.25-fold) (Fig. 2). In the data we received at the end of 48 h, a very serious decrease was observed in the amount of H₂O₂. As a result of 1 mM NaBu and 5 mM NaBu treatments compared to the control group (3.43 μM, 1.25-fold) (Fig. 2). In the data we received at the end of 48 h, a very serious decrease was observed in the amount of H₂O₂. As a result of 1 mM NaBu and 5 mM NaBu treatments compared to the control group (3.43 μM, 1.25-fold) (Fig. 2).

3.4. The effects of NaBu on the SOD activity

In our studies to determine the SOD enzyme activity, it was determined that the activities of the SOD enzyme decreased with increasing NaBu concentration compared to the control cells in both the 24-hour and 48-hour groups. In NaBu treatments, MCF-SOD enzyme activities were determined as a mean ± standard error of the mean (SD), and all experiments were conducted in triplicate. The p < .001 value was statistically significant, and GraphPad Prism 16 was employed while conducting statistical analysis.

The effects of NaBu on the SOD activity were determined by WST-1 analysis for 24 and 48 h (*p < .001).
The effects of NaBu on the NO levels

It was determined that there were no changes in nitric oxide (NO) amounts in the experimental group for 24 h compared to the control (0.92 μM) (0.83 μM and 0.92 μM (Table 1). In the 48-hour experimental group, a slight decrease was observed in the 1 mM NaBu treatments (5.49 μM) compared to the control group (6.11 μM), while a 1.3-fold increase was observed in the 5 mM NaBu treatments (10.94 ± 0.34 μM) compared to the control group (6.11 μM). (Fig. 2).

Table 1

| Time (Hours) | NaBu -Control x ± SD | MDA (μM) x ± SD | H2O2 (μM) x ± SD | SOD (U/mg) x ± SD | NO (μM) x ± SD | GSH (μM) x ± SD |
|--------------|----------------------|----------------|----------------|------------------|--------------|----------------|
| 24 h         | Control              | 3.07 ± 0.01    | 5.18 ± 0.41    | 10.71 ± 0.73     | 0.92 ± 0.04   | 0.02 ± 0.01   |
|              | 1 mM                 | 2.84 ± 0.02**  | 5.20 ± 0.25    | 8.92 ± 0.81**    | 0.83 ± 0.01   | 0.01 ± 0.02   |
|              | 5 mM                 | 3.12 ± 0.01**  | 6.28 ± 0.79**  | 6.24 ± 0.13**    | 0.90 ± 0.05   | 0.01 ± 0.01*  |
| 48 h         | Control              | 2.59 ± 0.02    | 8.81 ± 0.47    | 10.94 ± 0.34     | 6.11 ± 0.38   | 0.01 ± 0.02   |
|              | 1 mM                 | 2.59 ± 0.09    | 1.34 ± 0.09**  | 7.64 ± 0.40**    | 5.49 ± 0.16   | 0.01 ± 0.02   |
|              | 5 mM                 | 3.08 ± 0.01**  | 0.44 ± 0.16**  | 2.77 ± 0.46**    | 7.22 ± 0.19** | 0.02 ± 0.01** |

(*p < .05, ** p < .001).

3.5. The effects of NaBu on the NO levels

It was determined that there were no changes in nitric oxide (NO) amounts in the experimental group for 24 h compared to the control (0.92 μM) (0.83 μM and 0.92 μM (Table 1). In the 48-hour experimental group, a slight decrease was observed in the 1 mM NaBu treatments (5.49 μM) compared to the control group (6.11 μM), while a 1.3-fold increase was observed in the 5 mM NaBu treatments (10.94 ± 0.34 μM) compared to the control group (6.11 μM).
NaBu (7.22 μM) treatment (Fig. 2). The mean values and statistical data of the changes in NO amounts in the control group, 1 mM NaBu and 5 mM NaBu treated MCF-7 cells, are given in Table 1.

3.6. The effects of NaBu on the GSH amount

In our GSH data, there was a decrease in NaBu treatments in our 24-hour experimental group when the results were compared with those of the control group. Moreover, there was a 2.7-fold increase in the amount of GSH in the 5 mM NaBu treatments in our experimental group at the end of 48 h compared to the control group (Fig. 2). The mean values and statistical data of the changes in the amount of GSH in the control group, MCF-7 cells treated with 1 mM NaBu and 5 mM NaBu, are given in Table 1.

3.7. Evaluation of the genotoxic effects of NaBu

DNA damage (head DNA (%), tail DNA (%), tail moment, olive tail moment) data in the control group, MCF-7 cells treated with 1 mM NaBu and 5 mM NaBu compared to the control group for 48 h.

Table 2

| Time (Hours) | NaBu-Control | Head DNA (%) | Tail DNA (%) | Tail moment (μm) | Olive tail moment (μm) |
|--------------|--------------|--------------|--------------|------------------|-----------------------|
| 48 h         | Control      | x ± SD       | x ± SD       | x ± SD           | x ± SD                |
| 1 mM         | 20.99 ± 2.48 | 79.01 ± 2.48 | 29.65 ± 3.24 | 23.39 ± 3.08     |
| 5 mM         | 15.95 ± 2.79 | 84.05 ± 2.79 | 30.23 ± 0.51 | 25.63 ± 0.40     |

4. Discussion

Regulation of the homeostatic mechanism of cancer cell formation and metastasis depends on the balance between cancer cell growth and death (Mirzaei et al., 2016; Vafaei et al., 2019). In this context, some biochemical and genotoxic changes in the regulation of cell apoptosis caused by NaBu were evaluated together with this study. Our results demonstrated that NaBu reduced cell viability dose and time-dependent. Additionally, NaBu potentially induced GSH but decreased SOD enzyme activity at higher concentrations, but the level of MDA and NO decreased at a low concentration of NaBu. Also, H2O2 decreased after incubation with higher and lower concentrations of NaBu for only 48 h treatment, not 24 h in MCF-7 cells. Our comet assay results determined that higher concentrations of NaBu treatments increased DNA damage in MCF-7 cells compared to the control group, inconsistent with the biochemical parameter results. NaBu shows its anticancer and genotoxic effects in breast cancer, especially through antioxidant enzymes, one of the oxidative stress parameters. However, the anticancer and genotoxic effects of NaBu are changes in the oxidative stress parameters with time and treatment concentration of NaBu in MCF-7 cells.

Mutation in DNA repair mechanisms due to any factor can cause MDA-DNA adducts mutations (dot and frameshift), strand breaks, cell cycle arrest, and induction of apoptosis (Valko et al., 2007; Sies, 2015; Liguori et al., 2018). In recent studies, it has been shown by various researchers that the amount of MDA increased compared to the control group (Gonenc et al., 2001; Chole et al., 2010; Rašić et al., 2018). In the data we obtained, a slight decrease in the amount of MDA in the cells incubated with low-dose NaBu at the end of 24 h is an indication that NaBu reduces lipid peroxidation against cancer cells, while detection of a very slight increase in
high-dose NaBu treatments at the end of 48 h supports related data.

An upsurge in cellular levels of H2O2 has been associated with some major changes in cancer, such as DNA alterations, cell proliferation, metastasis, angiogenesis, and hypoxia-inducible factor 1 (HIF-1) activation (Graves, 2012; Pizzino et al., 2017). In contrast, it was also observed that H2O2 could selectively stimulate apoptosis in cancer cells and partially mediated the activity of several anticancer drugs frequently employed in clinical practice (Li et al., 2017; Rahman et al., 2019). Consistent with the literature, the very significant decrease in H2O2 amounts following NaBu treatment in the data we obtained at the end of 48 h reveal the H2O2 mediated anticancer activity of NaBu.

While many cancer cells have low levels of MnSOD proteins and enzymatic activity, some cancer cells have been reported to have high levels of MnSOD expression and activity (Dhar and Clair, 2012). Extracellular SOD (EcSOD) expression levels are significantly reduced in most cancers, including breast, head and neck, lung and sarcoma (Teng et al., 2012; Griess et al., 2017). Despite the marked decrease in EcSOD expression in breast carcinomas, an inverse correlation has been reported between EcSOD mRNA expression levels and breast cancer stage (Hubackova et al., 2012; Teoh-Fitzgerald et al., 2014). However, the Determination of the SOD level by specific oncogenic separators or by the general state of the entire redox system can make the situation more complex. Papa et al. (2014) showed in their study that decreased Cu/ZnSOD expression in some breast cancer cells caused a compensatory increase in MnSOD. In the data we obtained from our study, the activities of the SOD enzyme decreased with increasing NaBu concentration. As stated in the literature, this decrease, contrary to expectations, shows that there are significant changes in the level of SOD among cancer cells, indicating that there is differential regulation of SOD in cancer cells, and this regulation may be associated with a typical stage of cancer development.

Nitric oxide (NO) is a short-lived gas that is produced endogenously by Nitric oxide synthase (NOS) enzymes in the body and acts as a key signalling molecule in various physiological processes (Choudhari et al., 2013; Galadari et al., 2017). While nitric oxide (NO) plays a role as a mediator of the cancer phenotype, in some cases, it is also being investigated for therapeutic purposes due to its tumour suppressor properties (Choudhari et al., 2013; Li et al., 2017; Smeda et al., 2018). In the data we obtained, an increase was detected in the amount of NO in high dose NaBu treatment for 48 h, while a decrease was observed after low dose NaBu treatment after 24 h of treatment. The chemical and biochemical properties of NO, its interactions with cellular targets differ greatly due to the heterogeneity of tumours (Somasundaram et al., 2019; Khan et al., 2020). Understanding the complexity of NO’s role in cancer will contribute to cancer treatment processes. NO seems to have a stimulating or inhibitory role on cancer depending on various factors such as time and dose. The molecular events associated with these differences need to be studied extensively.

GSH has an important impact in the detoxification of carcinogens and appears as a target in developing new strategies to improve cancer treatment (Estrela et al., 2006; Ballatori et al., 2009). In our data, a significant increase in the amount of GSH, especially following high-dose NaBu treatment, reveals the GSH-mediated anticancer activity of NaBu in breast cancer cells.

DNA damages occur due to acute outcomes stemming from impaired DNA metabolism, stopping cell cycle progression or causing cell death (Liao et al., 2008). Single Cell Gel electrophoresis – i.e., a comet assay – is a method employed to determine DNA damages (Collins, 2004; Moller et al., 2020). The induction of DNA damage in cancer cells is a famous therapeutic technique for killing cancer (Liao et al., 2008). Researchers have reported that treatment with NaBu increases human endometrial cancer cell line intracellular ROS production and DNA damage response signals and induces DNA damage (Kato et al., 2011; Pant et al., 2017). Our results determined that NaBu treatments increased DNA damage in MCF-7 cells compared to the control group in Comet assay data. HDAC inhibitors can be used as an antimetabolite therapy according to their inhibitory impact on cancer cells.

5. Conclusions

The data we obtained revealed that NaBu shows its anticancer and genotoxic effects in breast cancer, especially through antioxidant enzymes, one of the oxidative stress parameters. However, this oxidative stress-dependent effect changes depending on dose and time, and this change needs to be clarified by further evaluation with molecular and more biochemical parameters. It is supported by the data we obtained that the detection of additional targets in breast cancer is highly encouraging. Prospective therapy developments will involve HDAC inhibitors and combination therapy using chemotherapy or other inhibitors.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Special thanks to Dr Ozlem AKSOY from the Department of Biology of Kocaeli University for providing the laboratory facilities.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

Alexieva, V., Sergiev, I., Mapelli, S., Karanov, E., 2001. Drought and ultraviolet radiation affect growth and stress markers in pea and wheat. Plant Cell and Environ. 24, 1337–1344. https://doi.org/10.1046/j.1365-3040.2001.00778.x.

Atala, E., Fuentes, J., Wehrhahn, M.J., Speisky, H., 2017. Quercetin and related flavonoids conserve their antioxidant properties despite undergoing chemical or enzymatic oxidation. Food Chem. 234, 479–485. https://doi.org/10.1016/j.foodchem.2017.05.023.

Ayala, A., Muñoz, M.F., Argüelles, S., 2014. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longevity 2014, 1–31.

Ballatori, N., Krance, S.M., Notenboom, S., Shi, S., Tieu, K., Hammond, C.L., 2009. Glutathione dysregulation and the etiology and progression of human diseases. Biol. Chem. 390, 191–214. https://doi.org/10.1515/BC2009033.

Bauer, G., 2019. The synergistic effect between hydrogen peroxide and nitrite, two long-lived molecular species from cold atmospheric plasma, triggers tumor cells to induce their own cell death. Redox Biol. 26, 101291. https://doi.org/10.1016/j.redox.2019.101291.

Bolden, J.E., Pearl, M.J., Johnston, R.W., 2006. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug. Discov. 5 (9), 769–784. https://doi.org/10.1038/nrd2133.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394–424. https://doi.org/10.3322/caac.21492.

Chio, I.L.C., Toveyson, D.A., 2017. ROS in cancer: the burning question. Trends. Mol. Med. 23 (5), 411–429. https://doi.org/10.1016/j.molmed.2017.03.004.

Chole, R.H., Patil, R.N., Basak, A., Palanduruk, K., Bhote, R., 2010. Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse. J. Cancer Res. Ther. 6, 487–491. https://doi.org/10.4103/0973-1964.71168.

Choudhari, S.K., Chaudhary, M., Bagde, S., Gadkari, A.R., Joshi, V., 2013. Nitric oxide and cancer: a review. World J. Surg. Oncol. 11, 118. https://doi.org/10.1186/1477-7819-11-118.
Collins, A.R., 2004. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol. Biotechnol. 26 (3), 249–261. https://doi.org/10.1385/MB:26:3:249.

Del Rio, D., Stewart, L., and Pellegrini, N., 2005. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 15, 316–328. https://doi.org/10.1016/j.numecd.2005.05.075.

Dhar, S.K., St. Clair, D.K., 2012. Manganese superoxide dismutase regulation and cancer. Free Radic. Biol. Med. 52 (11–12), 2209–2222. https://doi.org/10.1016/j.freeradbiomed.2012.03.009.

Dhar, P., Kumbhare, V., Mor, R., 2001. Differential antioxidative responses to cadmium in roots and leaves of Pisum sativum L. cv. Azad). J. Exp. Bot. 52, 1101–1109. https://doi.org/10.1093/jxb/52.358.1101.

Eckschläger, T., Pich, J., Stiborova, M., Hrabeta, J., 2017. Histone deacetylases inhibitors as antibacterial drugs. Int. J. Mol. Sci. 18, 1414. https://doi.org/10.3390/ijms18071414.

Estrela, J.M., Ortega, A., Obrador, E., 2006. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43 (2), 143–181. https://doi.org/10.1080/1040835050052878.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.

Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer development, prevention and treatment. Int. J. Oncol. 19, 221–236. https://doi.org/10.3892/ijo.2014.2221.
and chemoresistance. Oxid. Med. Cell. Longevity 2013, 1–10. https://doi.org/10.1155/2013/972913.
Tripathi, B.N., Gaur, J.P., 2004. Relationship between copper- and zinc- induced oxidative stress and proline accumulation in Scenedesmus sp. Planta 219, 397–404. https://doi.org/10.1007/s00425-004-1237-2.
Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T.D., Mazur, M., Telser, J., 2007. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39 (1), 44–84. https://doi.org/10.1016/j.biocel.2006.07.001.
Waks, A.C., Winer, E.P., 2019. Breast cancer treatment: a review. Jama 321 (3), 288. https://doi.org/10.1001/jama.2018.19323.
Vafaei, S., Fattahi, F., Ebrahimi, M., Janani, L., Shariftabrizi, A., Madjd, Z., 2019. Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review. Cancer Manage. Res. 11, 8669. https://doi.org/10.2147/CMAAR.S219699.
Yi, J.F., Li, Y.M., Liu, T., He, W.T., Li, X., Zhou, W.C., Kang, S.L., Zeng, X.T., Zhang, J.Q., 2010. Mn-SOD and CuZn-SOD polymorphisms and interactions with risk factors in gastric cancer. World J. Gastroenterol. 16, 4738–4746. https://doi.org/10.3748/wjg.v16.i37.4738.
Yuksel, B., Deveci Ozkan, A., 2021. The role of citrus nobiletin on oxidative stress levels and superoxide dismutase activities in metastatic castration-resistant prostate cancer. Commagene Biol. 5, 84–89 https://doi.org/10.31594/commagene.895415.
Zendehdel, M., Niakan, B., Keshtkar, A., Rafiei, E., Salamat, F., 2018. Subtypes of benign breast disease as a risk factor for breast cancer: a systematic review and meta-analysis protocol. Iranian J. Med. Sci. 43, 1–8.